July 2019
Volume 60, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2019
Safety of autologous bone marrow mesenchymal stem cells subretinal transplantation in diabetic retinopathy patients
Author Affiliations & Notes
  • Yong Liu
    Dept of Ophthalmology, Southwest Hospital, Chongqing, China
  • Qing Ling Liang
    Dept of Ophthalmology, Southwest Hospital, Chongqing, China
  • Zheng Qin Yin
    Dept of Ophthalmology, Southwest Hospital, Chongqing, China
  • Footnotes
    Commercial Relationships   Yong Liu, None; Qing Ling Liang, None; Zheng Qin Yin, None
  • Footnotes
    Support  National Key Research Program 2016YFC1101103 in China
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 3931. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Yong Liu, Qing Ling Liang, Zheng Qin Yin; Safety of autologous bone marrow mesenchymal stem cells subretinal transplantation in diabetic retinopathy patients. Invest. Ophthalmol. Vis. Sci. 2019;60(9):3931. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To investigate the safety of transplantation of the autologous bone marrow mesenchymal stem cells (ABMSCs) into the subretinal space for the treatment of proliferative diabetic retinopathy (PDR).

Methods : Patients diagnosed with PDR were enrolled in this study followed the inclusion criteria. All patients were examined specially in ophthalmology and treated with ABMSC transplantation in the subretinal space,and were followed up for 12 months after transplantation.

Results : Four patients diagnosed as PDR were enrolled in this study. All patients were performed ABMSC transplantation, and no one felt discomfort after treatment. FFA and OCT showed that the transplanted cells were present in the subretinal space until 1 month after transplantation. One patient diagnosed as macular edema preoperatively was relived gradually after transplantation, and effect lasted 3 months after transplantation. BCVA of the two subjects were improved from HM to 20/20(84 ETDRS),and from CF to 20/200(38 ETDRS) after transplantation separately, and of the other two stable. All patients underwent panretinal photocoagulatio 3 months after transplantation, and the follow-up treatment complied with the routine of post-vitrectomy for diabetic retinopathy, no complications occurred.

Conclusions : Subretinal transplantation of ABMSC for PDR is safe. The transplanted cells showed local anti-inflammatory effect, and no effect on cell proliferation or circulatory improvement were observed.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×